วารสารสมาคมจิตแพทย์แห่งประเทศไทย
Journal of the Psychiatrist
Association of Thailand
ISSN: 0125-6985
บรรณาธิการ มาโนช หล่อตระกูล
Editor: Manote
Lotrakul, M.D.
วารสารสมาคมจิตแพทย์แห่งประเทศไทย
Journal of the Psychiatric association of Thailand
สารบัญ (content)
pdf
format
Bioequivalence
of Clozapine Tablets
Wandee Taesotikul,
M.Sc.(Pharmacology)*
Sayam Kaewvichit, Ph.D.(Pharmacy)*
Chokchai Wongsinsup,
M.Sc.(Pharmacy)*
Chuleegone Sornsuvit,
M.Sc.(Pharmacy)*
Kittipong Sanichwankul,
M.D., Dip. in Psychiatry**
Wanida Pumpaisalchai,
M.Sc.(Biopharmacy)**
Abstract
Objective To perform
a bioequivalence study of clozapine tablets between Clozaril? tablet
(Novartis), the innovator product, and Clopaze? tablet (Pharminar,
Thailand).
Method
The study was performed in 12 healthy male volunteers for a
single 100 mg dose of clozapine tablet. Randomized cross over design
was used. Blood samples were collected before and after drug administration
for 24 hours and determined for plasma clozapine concentration by
HPLC method.
Results
The results of the bioequivalence study of 100 mg clozapine tablets
showed a high variation in pharmacokinetic parameters of both Clozaril?
and Clopaze? similar to those reported elsewhere. When statistics
were tested as stated in USP23 guideline for bioequivalence study,
90% confidence interval of the log of ratio of Cmax,
AUC24hr and AUCinf between Clopaze? and Clozaril?
were within the range of 0.80 - 1.25.
Conclusion
It can be indicated that the 100 mg Clozaril? and Clopaze? tablets
used in this study are bioequivalent to each other.
J Psychiatr
Assoc Thailand 2000; 45(3): 221-227.
Key words
: bioequivalence, clozapine
* Biopharmacy
Research Unit, Faculty of Pharmacy, Chiang Mai University, Chiang
Mai 50200.
** Suanprung Psychiatric Hospital,
Chiang Mai 50100.
ชีวสมมูลของยาเม็ดโคลซาปีน
วรรณดี แต้โสตถิกุล
วทม.(เภสัชวิทยา)*
สยาม แก้ววิชิต PhD. (Pharmacy)*
โชคชัย วงศ์สินทรัพย์ วทม.(เภสัชศาสตร์)*
ชุลีกร สอนสุวิทย์ วทม.(เภสัชศาสตร์)*
กิตติพงศ์ สานิชวรรณกุล พบ., วว.(จิตเวชศาสตร์)**
วนิดา พุ่มไพศาลชัย
วทม.(ชีวเภสัชกรรม)**
บทคัดย่อ
วัตถุประสงค์ เพื่อศึกษาชีวสมมูลของยาเม็ดโคลซาปีนระหว่างผลิตภัณฑ์ต้นแบบ
คือ ยา Clozaril? ของบริษัท Novartis กับผลิตภัณฑ์ที่ผลิตในประเทศไทย
คือ ยา Clopaze? ของบริษัท Pharminar
วิธีการศึกษา ศึกษาในอาสาสมัครชายสุขภาพดี
12 คน โดยการให้อาสาสมัครรับประทานยาเม็ด
โคลซาปีนในขนาด 100 มิลลิกรัม การศึกษาเป็นแบบสุ่มสลับ เก็บตัวอย่างเลือดของอาสาสมัครก่อนและหลังรับประทานยาที่เวลาต่างๆ
ในช่วง 24 ชั่วโมงหลังการให้ยา และวิเคราะห์หาความเข้มข้นของยาในพลาสมาโดยวิธี
HPLC
ผลการศึกษา พบว่าค่าตัวแปรทางเภสัชจลนพลศาสตร์ของยา
Clozaril? และ Clopaze? ขนาด 100 มิลลิกรัม/เม็ด มีความแปรปรวนสูงคล้ายคลึงกับที่ได้มีการรายงานไว้แล้ว
เมื่อนำไปทดสอบทางสถิติโดยวิธีที่กำหนดไว้ใน USP 23 พบว่า ค่าตัวแปรทางเภสัชจลนพลศาสตร์ของยาทั้งสองไม่แตกต่างกัน
โดยมี 90% Confidence Interval ของอัตราส่วนของความเข้มข้นสูงสุดของยาในพลาสมา
(Cmax) หรือพื้นที่ใต้เส้นโค้งของกราฟความสัมพันธ์ระหว่างความเข้มข้นของยาในพลาสมากับเวลาช่วง
24 ชั่วโมง (AUC24hr) กับเวลาอนันต์ (AUCinf)
ในรูปลอการิทึมระหว่าง Clopaze? กับ Clozaril? อยู่ในช่วงที่ USP กำหนด
(0.80 1.25)
สรุป ยา Clozaril? และ
Clopaze? ในขนาด 100 มิลลิกรัม/เม็ด ที่ใช้ในการศึกษาครั้งนี้มีชีวสมมูลซึ่งกันและกัน
วารสารสมาคมจิตแพทย์แห่งประเทศไทย
2543; 45(3): 221-227.
คำสำคัญ ชีวสมมูล โคลซาปีน
* หน่วยวิจัยชีวเภสัชกรรม
คณะเภสัชศาสตร์ มหาวิทยาลัยเชียงใหม่ จังหวัดเชียงใหม่ 50000
** โรงพยาบาลสวนปรุง อำเภอเมือง
จังหวัดเชียงใหม่ 50000
Introduction
Clozapine,
a dibenzodiazepine derivative (piperazine-substituted tricyclic
antipsychotic agent), is prescribed for treatment of refractory
schizophrenia or for the patients who can not tolerate the extrapyramidal
adverse effects of conventional antipsychotic medications1.
Clozaril? , the innovative drug, was marketed in Thailand in the
dosage of 25 and 100 mg/tablet. As well as the fact that it is quite
expensive, the information on the pharmacokinetics of clozapine
in Thais is insufficient. The information regarding bioequivalence
study between Clozaril? and Clopaze? , product made in Thailand,
will be helpful for physicians, pharmacists, and drug consumers
for appropriate selection of drug. Confidence in therapeutic efficacy
will be enhanced.
Materials
and methods
The bioequivalence
study between Clozaril? and Clopaze? tablets was approved by the
Human Experimentation Committee, Research Institute for Health Sciences
(RIHES), Chiang Mai University. The study was performed at Suanprung
Psychiatric hospital, Chiang Mai. Plasma clozapine analysis and
data analysis were executed at the Biopharmacy Research Unit, Faculty
of Pharmacy, Chiang Mai University.
Volunteers:
Volunteers were 12 healthy Thai males; their average age, weight,
and height were 21.4 ? 1.2 years (range 18 - 24), 59.4 ? 5.8 kg
(range 53 - 70), and 168 ? 7 cm (range 153 - 175), respectively.
Their body mass indexes were within the range of 18-24 kg/m2.
A physical examination as well as all clinical and routine laboratory
evaluation tests for all volunteers, such as complete blood count,
blood urea nitrogen, and liver function test, were within medically
acceptable limits. None of them had a history of alcoholism, smoking,
hepatic disease, active peptic ulcer disease and renal insufficiency.
Before joining the study, all volunteers were informed of the details
of the study, and signed a consent form. All volunteers were free
to leave the study at any time.
Study design:
A randomized, double blind, two-period crossover design was used
with one week washout period. All subjects, physician and drug analyst
were blinded. The innovator and test products, in the dosage of
100 mg/tablet, are Clozaril? (Lot No. 119, Novartis) and Clopaze?
(Lot No. AK21801, Pharminar), respectively. These two clozapine
tablets had already passed the content uniformity test.
One week before
and during the period of the study, all volunteers had took no medicine
and consumed no alcoholic beverages. Food had been abstained from
8.00 pm the night before the study. One tablet of either Clozaril?
or Clopaze? , following the randomly assigned order, was taken by
each volunteer at 8.00 am with 200 ml water.
Ten milliliters
of blood samples were taken at 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5,
6, 8, 12 and 24 hour(s) after drug taking and, then centrifuged
to separate plasma within half an hour. Plasma samples were stored
at -48? C. The plasma samples were analysed for clozapine content
within one week of storage.
Clozapine
analysis: Clozapine content was analyzed by a modified High
Performance Liquid Chromatography2. Plasma 2.0 ml was
pipetted and mixed with 500 m l of saturated tribasic sodium phosphate
using vortex mixer for 1 minute. Two milliliters of chloroform were
added using vortex mixer for 5 minutes and then centrifuged at 4500
rpm for 10 minutes. Chloroform layer, 1.5 ml, was collected and
then dried at 40 oC under low pressure (HBI Vortex-Evaporator?
, Buchler Instruments, USA). Residue was dissolved with 200 m l
mobile phase composed of 500 ng/mL indomethacin using as an internal
standard. Then, 100 m L of the solution was injected onto a reverse
phase Hypersil? ODS column (C18, 250x4.6 mm, 5 m m) connecting with
a Hewlett Packard Series 1100 HPLC system (G1356AA, Germany) equipped
with UV detecter. The mobile phase was phosphate buffer pH 3.52
: Acetonitrile (50:50) using with a flow rate of 1.5 mL/min. The
UV detection was performed at 240 nm.
Standard curves
were performed by preparing standard clozapine (Batch 981106, Zhejiang
Wenling Pharmaceutical Factory, China) in plasma with the concentration
of 20, 50, 100, 200, 500 ng/ml. Previous mentioned extraction process
was performed and injected into the HPLC system.
Linearities
of the standard curves were found in the range from 20 - 500 ng/ml
(r2>0.9950). Intraday and interday variation were
determined before being used for the analysis of plasma clozapine
content by performing of 3 standard curves daily for 3 days. The
relative standard deviations at each concentration were less than
10%. Recovery percentage of the analysis method at high, medium
and low concentration were more than 95 %. The lower limit of detection
was less than 20 ng/mL. However, standard curves were performed
every day of analysis.
Data analysis:
Pharmacokinetic parameters were determined. Cmax
and Tmax were taken from the raw data. AUC was determined
using trapezoidal rule. Elimination rate constant (ke)
was determined from the slope of the last portion of the log concentration
- time curves and subsequently elimination half-life (t1/2)
was also calculated.
Statistical
methods: Bioequivalence testing comprised of assessment with
respect to the rate (Cmax) and extent (AUC24hr
and AUCinf ) of clozapine absorption4. The
division of Bioequivalence of the United State of America has employed
a testing procedure termed the two one-sided tests procedure to
determine whether average values for pharmacokinetic parameters
measured after administration of the test and reference products
are comparable. This procedure involves the calculation of a 90%
confidence interval for the ratio of the product averages. The Cmax,
AUC24hr and AUCinf were analyzed statistically
by logarithmically transformed. The 90% confidence interval for
the difference in the means of the log-transformed data was calculated
using the following equation3-5:
90% confidence
interval = D ? t0.10, n ? EMS(2/n)
Where D is
a difference in means of log transformed pharmacokinetic parameters
(Cmax or AUC24hr or AUCinf) between
the test product and the reference, t0.10, n is the tabulated
two-tail t value for a 90% confidence interval, n is a degree of
freedom of the error mean square obtained from the ANOVA table,
EMS is the error mean square from the ANOVA table and n is the number
of subjects. Antilogarithm of the calculated confidence interval
will yield an exact confidence interval for the ratio. For the bioequivalence
between the test and reference products, USP 23 required that a
90% confidence interval of the ratio of means of the pharmacokinetic
parameters, ie. Cmax, AUC24hr and AUCinf
must be in the range of 0.80 1.254.
Results
All volunteers
who took either Clozaril? or Clopaze? slept within 30 minutes after
the dose. Side effect, sialorrhea, was similarly found for both
products in about 50% of the volunteers. They woke up around 7.00
pm for dinner, and continued sleeping until the next morning.
Average clozapine
concentration time curves of Clozaril? and Clopaze? tablets are
demonstrated in Figure 1. Biphasic clozapine blood levels for both
Clozaril? and Clopaze? tablets were seen in most volunteers.
Pharmacokinetic
parameters, ie. AUC24hr, AUCinf, Cmax,
Tmax , are collated in Table 1. AUC24hr were
3015.05 ? 608.83 and 2793.22 ? 740.33 ng.hr/ml and AUCinf
were 3755.74 ? 837.28 and 3366.97 ? 1036.28 ng.hr/ml for Clozaril?
and Clopaze? respectively. Average Cmax were 308.31 ?
89.65 ng/mL and 315.75 ? 81.98 ng/mL for Clozaril? and Clopaze?
respectively. Average elimination rate constant was 0.08? 0.02 hr-1
and 0.07? 0.02 hr-1 for Clozaril? and Clopaze? respectively.
Tmax varied highly for the data both from those taking
Clozaril? (142.75 ? 133.59 minutes) and Clopaze? (100.00 ? 69.28
minutes).
90% confidence
interval of the ratio of AUC24hr, AUCinf and
Cmax between Clopaze? and Clozaril? were 0.91-1.01, 0.88-0.98
and 0.97-1.24 respectively.
Discussion
Biphasic clozapine
blood levels which were seen in most volunteers for both Clozaril?
and Clopaze? tablets might be expected since the volunteers were
in the fasting condition and slept for about 12 hours. This characteristic
has been noted before6 and it was found in many other
antipsychotic agents7,8.
High variation
in all pharmacokinetic parameters agree with the high interindividual
variation which had been previously reported9-12. The
biphasic blood level was possibly the reason for the high variation
of both Clozaril? and Clopaze? . Additionally, the considerable
variation of plasma levels of clozapine had been reported (about
fivefold to eightfold), not only among the patients receiving the
same daily doses, but also in individual patients over time8.
Variation in the absorption of the drug was a suggested reason rather
than variation in the hepatic metabolism and clearance.
90% confidence
interval of the ratio of Cmax, AUC24hr and
AUCinf between Clopaze? and Clozaril? were in a range
of 0.80 - 1.25 as those stated in USP 23. Therefore, bioequivalence
can be indicated between Clopaze? and Clozaril? .
It should be
noted that this finding was limited only for the lot used in the
study. In addition, this study was designed as a single dose administration
in healthy volunteers, therefore, long term use in patients should
be considered regarding the therapeutic effect. However, a report
has stated that, for clozapine, there is no correlation between
blood concentration and its therapeutic effect11. Thus,
when clozapine is used to treat patients, dose titration has to
be carried out from a low dose to a high dose until the effective
dose for each patient is acheived1,10. Therapeutic drug
monitoring may also be performed for a rapid dosage regimen adjustment1.
Conclusion
The results
of the bioequivalence study revealed a high variation in pharmacokinetic
parameters of both Clozaril? and Clopaze? , 100 mg/tablet, as had
been reported elsewhere. When statistics were tested as stated in
USP guideline for bioequivalence study, 90% confidence interval
of the log of ratio of Cmax, AUC24hr or AUCinf
between Clopaze? and Clozaril? were within the range of 0.80 - 1.25.
Therefore, it can be indicated that the 100 mg Clozaril? and Clopaze?
tablets used in this study are bioequivalent to each other.
References
1. Freeman
DJ, Oyewumi LK. Will routine therapeutic drug monitoring have a
place in clozapine therapy? Clin Pharmacokinet 1997; 32:93-100.
2. Lunn G,
Schmuff NR. HPLC methods for pharmaceutical analysis. New York:
John Wiley & Sons, 1997:400-11.
3. Tengamnuay
P. Guidelines for bioavailability/bioequivalence studies. Bangkok:
Department of Medical Sciences, Ministry of Public Health, 1992:48-56.
4. USP 23,
NF 18: The United States Pharmacopeia, The National Formulary. Rockville,
MD: The United States Pharmacopeial Convention, 1995:1838-9, 1930-8.
5. Bolton S.
Pharmaceutical statistics: practical and clinical application. 3rd
ed. New York: Marcel Dekker, 1997:401-18.
6. AHFS Drug
Information. Bethesda, MD: The American Society of Health-System
Pharmacists, 1999:2071-2.
7. Baldessarini
RJ, Cohen BM, Teicher MH. Significance of neuroleptic dose and plasma
level in the pharmacological treatment of psychoses. Arch Gen Psychiatry
1988; 45: 79-91.
8. Baldessarini
RJ, Frankenburg FR. Clozapine: A novel antipsychotic agent. N Engl
J Med 1991; 324:746-54.
9. Ackenheil
M. Clozapine pharmacokinetics investigations and biochemical effects.
Psychopharmacology 1989; 99:532-7.
10. Martindale:
The Extra Pharmacopoeia. Volume 1. 30th ed. Singapore: Info Access
& Distribution, 1994:583-93.
11. Jann MW,
Grimsley SR, Gray EC, Chang WH. Pharmacokinetics and Pharmaco- dynamics
of Clozapine. Clin Pharmacokinet 1993; 24:161-76.
12. Drug Facts
and Comparisons 1997 edition. St. Louis, MO: Facts and Comparisons,
1997:1615-20.
Figure 1 Average plasma clozapine concentration at various
sampling times. ( ? ) Clozaril? ( ) Clopaze? (n=12)
Table
1 Pharmacokinetic parameters of Clozaril? and Clopaze? (n=12)
Pharmacokinetic
parameters
|
Clozaril?
|
Clopaze?
|
90
% Confidence Interval
of
the ratio
|
AUC24hr
* (ng.hr/ml)
|
3015.05
? 608.83
|
2793.22
? 740.33
|
0.91-1.01
|
AUCinf
*(ng.hr/ml)
|
3755.74
? 837.28
|
3366.97
? 1036.28
|
0.88-0.98
|
Cmax
* (ng/ml)
|
315.75
? 81.98
|
308.31
? 89.65
|
0.97-1.24
|
Tmax
(min)
|
142.75
? 133.59
|
100.00
? 69.28
|
|
Ke
(hr-1)
|
0.07
? 0.02
|
0.08
? 0.02
|
|
T1/2
(hr)
|
10.09
? 2.67
|
9.21
? 2.09
|
|
* Log data
transformation
|